AACR-Lung Cancer Initiative at Johnson & Johnson – Stimulating Therapeutic Advances Through Research Training (START) Grant
Closing Date: 01/06/2022
Grants to support collaborative cancer research to bolster understanding of how lung cancer can be successfully intercepted. Grants must be hosted in the US and submitted by researchers belonging to NIH-defined underrepresented groups.
The American Association for Cancer Research (AACR) is a large professional organisation dedicated to advancing cancer research. Its mission is to prevent and cure cancer through research, education, communication and collaboration.
Significant advances made in recent years towards precision medicine initiatives, biomarker and novel target identification, and high-throughput examination of genomic data, have resulted in a wealth of valuable data that can inform the development of new therapeutics to combat cancer. However, to effectively harness this information and advance the discovery and development of new therapies for cancer patients, enhanced collaboration between academia and industry will be needed.
The AACR-Lung Cancer Initiative at Johnson & Johnson Stimulating Therapeutic Advances through Research Training (START) Grants has been established to address the need to support such collaborations. The grants will provide support to postdoctoral or clinical research fellows from underrepresented groups and will combine research experiences in both academic and industry settings, following a research timeline that will be of greatest benefit to the proposed work.
This grants program also intends to build a more diverse and inclusive future for immuno-oncology lung cancer researchers. Eligibility is limited to individuals from underrepresented groups as per NIH guidelines. The training provided will provide fellows with a comprehensive research experience, enhancing their appeal to potential academic and industrial employers.
Research proposals may be translational or clinical in nature but must have direct applicability to lung cancer. Proposals focused on the following are highly encouraged:
- Mechanisms linking immunogenic cell death pathways to amplification of innate and adaptive immunity.
- Immunobiology of non-small cell lung cancers.
- Mechanisms of acquired resistance to immunotherapies.
Applicants may spend one year on site at a Johnson & Johnson Enterprise Innovation facility at the discretion of Johnson & Johnson Enterprise Innovation. One of a number of Johnson & Johnson Enterprise Innovation’s locations are possible, at the discretion of Johnson & Johnson Enterprise Innovation.
The year at Johnson & Johnson Enterprise Innovation will be determined on a case-by-case basis and will be at a time agreed upon by the fellow, the academic supervisor, the Johnson & Johnson Enterprise Innovation mentor, and Johnson & Johnson Enterprise Innovation.
|Funding body||American Association for Cancer Research (AACR)|
|Maximum value||225,000 USD|
|Fund or call||Fund|